The Cardio Diabetes Master Class was a dynamic meeting with state of the art lectures, clinical debates and practical workshops. Participants are part of an ongoing educational initiative that support clinicians in their daily clinical management of cardiovascular risk and diabetes. As an educational service teaching slides developed and presented by faculty are available to view and download for participants
The program of this Master Class, entitled:
T2DM management in high CV risk patients: What are the Facts and Opportunities?
was designed to provide the participants with new information and perspectives on effective strategies to help patients, with diabetes and/or increased cardiovascular risk to reach their treatment goals.
The educational objectives of the program were:
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and diabetes
- To review and discuss the importance of glucose management and the rationale for early intervention strategies in patients with diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of DPP4 inhibitors and TZD’s, in a riskbased intervention strategy that targets glucose control and cardiovascular risk factors
- To discuss therapies that work through other insulin-related mechanisms, including insulin resistance in order to reduce the incidence of cardiovascular events; especially in high-risk patient populations with a history of an ACS event and multiple risk factors
- To evaluate the current guidelines for the management of patients with diabetes and high CV risk, and identify potential novel targets for therapy in this high-risk patient group
- To discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multirisk patients
CME accreditation was accredited by the European Board for accreditation in Cardiology (EBAC) with
endorsement of the Gulf Heart Association.
The programme is funded by an unrestricted educational grant provided by Takeda Pharmaceuticals
Meeting resources (more to follow)
3 minute education • 6-5-2016, Dubai, UAE, Dr Robert J Chilton
Dr. Robert Chilton, (Texas) discusses the results of the IRIS trial where treatment with PPAR-γ agonist pioglitazone
3 minute education • 6-5-2016, Dubai, UAE, Dr Sanjay Rajagopalan, MD, Maryland
Dr Rajagopalan, MD, Maryland, USA reviews the utility of DPP4 inhibitors in T2DM patients with high risk CVD
Presentation prepared and held by dr Sanjay Rajagopalan, Maryland, USA at the CME accredited 'Cardio Diabetes Master Class' held on April 15-16, 2016 in Dubai, UAE.
Presentation prepared and held by Prof Kausik Ray, Imperial College London at the CME accredited 'Cardio Diabetes Master Class' held on April 15-16, 2016 in Dubai, UAE.
Presentation prepared and held by Prof Robert Chilton, San Antonio, Texas, USA at the CME accredited 'Cardio Diabetes Master Class' held on April 15-16, 2016 in Dubai, UAE
Understanding the natural course of diabetes and CVDProf Kausik Ray, MD, Imperial College London, UK
| ||Tarek Mohamed Fiad, MD - Sheik Khalifa Medical City|
Abu Dhabi, UAE
|Dr. Iyad Ksseiry, M.D. Dubai, UAE|
| ||Sanjay Rajagopalan, MD - Maryland, USA|
| ||Robert J. Chilton, MD, San Antonio, Texas, USA|